Bruce Linton & Kevin O’Leary Invest in Psychedelics
February 6th, 2020
The cannabis industry has matured into a multi-billion dollar market over the past several years — and many of its pioneers are moving on to earlier stage opportunities.
Shark Tank’s Kevin O’Leary, better known as Mr. Wonderful, and former Canopy Growth Corp. (NYSE: CGC) (TSX: WEED) Founder & CEO Bruce Linton recently made investments into the MindMed — an early pioneer in the psychedelics space. The $6.2 million investment round made headlines throughout the cannabis space and could represent another big regulatory-driven opportunity.
MindMed was founded by Silicon Valley tech executive JR Rahn and 35-year biopharmaceutical industry veteran Stephen L. Hurst, JD, who were interested in developing outside-of-the-box solutions to mental illnesses ranging from depression to addiction. After spending years researching the industry, the two opted to take a company down the regulatory pathway.
MindMed is gearing up for a Phase II clinical trial focused on Attention Deficit Hyperactivity Disorder (ADHD) where participants will receive a micro dose of LSD to increase focus and creativity. Taking a page out of the CBD playbook, these dosages would not be high enough to elicit any hallucinogenic effects, making them more palatable for doctors to prescribe.
In addition, the company is working on a non-hallucinogenic synthesized version of Ibogaine, a naturally-ocucring psychoactive substance found in plants. The team recently acquired an anti-addictive molecule that was previously funded by the National Institute on Drug Abuse and plans to develop a Phase II clinical trial to treat addiction.
The move comes as psilocybin and other psychedelics have earned legal status across many U.S. municipalities, including Denver, Colorado and parts of California. Advocates from Oregon and California hope to bring a legalization question to the 2020 ballot for a statewide vote — and existing cannabis frameworks could ease the legalization process.
Like cannabis, many psychedelics have a long track record of safety among recreational users. There’s also evidence that they could be beneficial for treating certain medical conditions. However, both psychedelics and cannabis remain Schedule I Controlled Substances on the Drug Enforcement Agency’s list with no signs of a federal removal.
Investors interested in the space may want to take a look at a handful of other companies that are starting to build a presence in the space during the early innings.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.